Home > Focus Areas > DLBCL Connect > Post
4yr
CD19 CAR-T expressing PD-1/CD28 chimeric switch receptor as a salvage therapy for DLBCL patients treated with different CD19-directed CAR T-cell therapies
Source : https://jhoonline.biomedcentral.com/articles/10.1186/s13045-021-01044-y
CD19-targeted chimeric antigen receptor T (CAR T) cell therapy is a promising option to treat relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL). However, the majority of CAR T-treated patients will eventually progress and require salvage treatment, for which there is no current standard.
-
Mark Fesler4yrThis work is somewhat preliminary but promising in that 50% of patients with a CaR enhancement achieved CR who failed prior standard CaR T ... will be interesting to continue to follow these CaR T enhancements ...